Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Patient perspective on drug shortages

2012 ASCO Annual Meeting

Published: 4 Jun 2012

Views: 3914

Rating:

Save

Dr Michael Link - Stanford University School of Medicine, California, USA

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, ASCO President Dr Michael Link discusses his experience with drug shortages and how his patients felt about the situations.

Related Videos

ASCO's strategic plan for cancer care in LMICs

Dr Lynn Schuchter - President, American Society of Clinical Oncology (ASCO), USA

ASCO's strategic plan for cancer care in LMICs ( Dr Lynn Schuchter - President, American Society of Clinical Oncology (ASCO), USA )

Gender inequity in ovarian cancer research in resource limited settings

Dr Khalid El Bairi - Mohamed First University, Oujda, Morocco

Gender inequity in ovarian cancer research in resource limited settings ( Dr Khalid El Bairi - Mohamed First University, Oujda, Morocco )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

Introducing oncology to undergraduate medical and allied health sciences...

Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India

Introducing oncology to undergraduate medical and allied health sciences students ( Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India )

Patient benefit vs industry benefit finding a balance

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Patient benefit vs industry benefit finding a balance ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Balancing innovation and Common Sense In Oncology (CSO)

Prof Richard Sullivan - King's College London, UK

Balancing innovation and Common Sense In Oncology (CSO) ( Prof Richard Sullivan - King's College London, UK )

Common Sense in Oncology – Why

Dr Christopher Booth - Queen's University, Canada

Common Sense in Oncology – Why ( Dr Christopher Booth - Queen's University, Canada )

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall...

Dr Neil Gross - MD Anderson Cancer Center, Houston, USA

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC ( Dr Neil Gross - MD Anderson Cancer Center, Houston, USA )

More from ecancer